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Abstract – The long pentraxin 3 (PTX3) plays an important role in host defence and its over-expression
may contribute to airway injury. The aim of the present study was therefore to characterize in more detail
PTX3 and its expression in the horses’ airway. Six healthy horses and six horses affected by recurrent
airway obstruction (R.A.O.) were submitted to a dusty environment challenge. PTX3 DNA and cDNAwere
cloned and sequenced. PTX3 expression was evaluated by RT-qPCR, Western blotting and immuno-
histochemistry in bronchoalveolar lavage ﬂuid (BALF) cells, BALF supernatant and bronchial epithelial
cells. An alternative splicing of the second exon of PTX3 occurred, resulting in two forms of the protein:
‘‘spliced’’ (32 kDa) and ‘‘full length’’ (42 kDa). PTX3 was detected in BALF macrophages, neutrophils and
bronchial epithelial cells. It was over-expressed in the BALF supernatant from R.A.O.-affected horses in
crisis. However, dust was unable to induce PTX3 in BALF cells ex vivo, indicating that dust is an indirect
inducer of PTX3. Dust exposure in-vivo induced PTX3 in BALF macrophages but there was no signiﬁcant
difference between healthy and R.A.O.-affected horses. Conversely, PTX3 was over-expressed in the
bronchial epithelial cells from R.A.O.-affected horses in crisis. These data indicate a differential regulatory
mechanism in inﬂammatory and bronchial epithelial cells and offer therapeutically interesting perspectives.
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1. INTRODUCTION
The respiratory tract is continuously chal-
lengedwithpotentially infectivemicroorganisms
and noxious airborne substances. An effective
defense system is necessary for protecting the
respiratory tract from pathogen invasion [19].
Airways function not only as a physical barrier
but alsoasabiological sensor for invadingmicro-
organisms and cytokines, chemokines and other
inﬂammatory mediators they induce [15, 22].
These soluble factors, together with inﬁltrated
immune cells, can initiate local inﬂammatory
reactions designed to eliminate the invading
pathogens, dilute the pathogens’ products, limit
the damages, and eventually lead to recovery
[25]. However, excessive inﬂammation can
induce persistent tissue injury and cause morbid-
ity and mortality [25].
The long pentraxin 3 (PTX3) is a member of
the pentraxin family that includes short pentrax-
ins and long pentraxins. Human PTX3 (hPTX3)
comprises a C-terminal pentraxin-like domain of
203 amino acids (aa) and a 178 aa N-terminal
domain. It has a predicted molecular weight of
40.165 kDa. However, in sodium dodecyl
sulfate (SDS)-polyacrylamide gel electrophore-
sis (PAGE) under reducing conditions, the appar-
entmolecularweight is 45 kDa. This is due to the
presence of an N-glycosylation site in the
C-terminal domain [1].* Corresponding author: eve.ramery@ulg.ac.be
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On the contrary to short pentraxins (e.g.
C-reactive protein, serum amyloid P) that are
produced in the liver, PTX3 is produced by
diverse cell types, locally, at the site of inﬂamma-
tion. Its production is induced by pathogen rec-
ognition. It detects microbial moieties, activates
the classical pathway of complement and facili-
tates recognition by macrophages and dendritic
cells (DC) [8]. In studies involving transgenic
mice, it was shown that PTX3 over-expression
could be protective [5] or deleterious [23],
depending on the conditions.
Recurrent airway obstruction (R.A.O.) is a
common cause of chronic respiratorydisease that
occurs in mature horses stabled in a dusty envi-
ronment containing poor quality hay and straw.
It is characterized by episodes of acute airway
obstruction (crisis) followed by periods of clini-
cal remission, when horses are kept away from
the causative environment. The clinical manifes-
tations of R.A.O. are consequent to lower
airway inﬂammation and involvebronchospasm,
excess mucus production and airway hyperre-
sponsiveness to non-speciﬁc stimuli [20].
Evidence has accumulated that nucleated cells
from bronchoalveolar lavage ﬂuid (BALF) can
produce numerous inﬂammatory mediators,
such as interleukin (IL)-8, IL-1b and tumor
necrosis factor a (TNF-a) [9]. Identifying these
factors and their regulatory mechanisms will
help to understand the role of BALF cells in host
defense and inﬂammatory responses. Using
microarray, we recently reported 46 candidate
genes with differentially regulated expression
between horses suffering from R.A.O. and con-
trols [19]. In particular, the long pentraxin 3
(PTX3) (also called TNF-a-stimulated gene 14)
was highly over-expressed in BALF cells of
horses suffering from R.A.O. and this was con-
ﬁrmed by real time-quantitative polymerase
chain reaction (RT-qPCR).
PTX3 plays an important role in host
defense and is expressed by a wide range of cell
types and tissues. Particularly, over-expression
of PTX3 can contribute to airway injury [11].
The aim of the present study was therefore to
characterize in more detail PTX3 and its expres-
sion in airways. For this purpose, a naturally
occurring airway inﬂammatory disease in
horses, namely R.A.O., was used.
2. MATERIALS AND METHODS
2.1. In silico study
The human complementary desoxyribo-nucleo-
tide acid (cDNA) sequence of PTX3 (Accession
number: NM_002852) has been blasted on the
equinegenomeavailableonNCBI1.Moreover, homol-
ogies between human and equine PTX3 genomic
sequences have been searched using UCSC2. The
equine sequence for PTX3 cDNA obtained in this
experiment was blasted on non-human, non-mouse
expressed sequence tags (EST) available on NCBI.
2.2. Primers and antibodies (Ab)
All primers (Tab. I) were designed with
Amplify33 and Oligo6.84 software and purchased
from Eurogentec (Seraing, Belgium). The primary
antibody, a monoclonal rat anti-human PTX3
(MNB1) was purchased from Alexis (Axxora BVPA,
Zandhoven, Belgium). The secondary antibody, a
polyclonal rabbit anti-rat immunoglobulin/HRP
(No. P0450), was purchased from DakoCytomation
(Glostrup, Denmark). A rat IgG2b isotype control
(clone 141945) was purchased from R&D systems
(Oxon, UK). The speciﬁcity of the monoclonal anti-
body was tested in total protein extracts from equine
peripheral blood leukocytes.
2.3. Dusty environment challenge
Six adult half-blood horses diagnosed as affected
by R.A.O. (4 females and 2 geldings, median; ranges,
14.5; 9–22 years) and six considered free from respi-
ratory diseases (2 females and 4 geldings, median;
ranges, 17.5; 11–28 years) were investigated. The sta-
tus of the horses (healthy versus affected) was
assessed in agreement with the criteria determined
by the R.A.O. experts [20], i.e. by history, clinical
and endoscopic examination, functional tests
(impulse oscillometry, arterial blood gas analysis)
and BALF cell counts. Horses were vaccinated and
dewormed regularly. The protocol was approved by
the Ethics Committee of the University of Liege
(Belgium). After a period of 2 months at pasture,
all horses were exposed to irritants and aeroallergens
by stabling them in the same barn with straw bedding
and feeding poor quality, dusty hay for 2 weeks.
1 http://www.ncbi.nlm.nih.gov/
2 http://genome.ucsc.edu/
Vet. Res. (2010) 41:18 E. Ramery et al.
Page 2 of 10 (page number not for citation purpose)
2.4. BALF macrophage isolation
BALF was retrieved as previously described and
kept at 4 C until processed [27]. The cells were col-
lected from BALF by centrifugation for 10 min at
2 000 rpm, washed twice and suspended in phos-
phate buffered saline (PBS) supplemented with 2%
fetal calf serum (FCS). Ten mL of the mixture were
gently layered over 17 mL of room temperature hist-
opaque-1077 in a 25 mL centrifuge tube. Tubes were
then centrifuged for 10 min at 1 500 rpm and the
mononuclear cell layer was removed and washed
twice with PBS + 2%FCS. The cells were then sus-
pended in RPMI 1640-L glutamine supplemented
with 10% heat-inactivated FCS and 1% penicillin-
streptomycin. All cells were seeded in 6-well culture
plates and incubated at 37 C and 5% CO2 in a
humid atmosphere for 2 h. Non-adherent cells were
rinsed out with two washes of PBS + 2%FCS.
2.5. BALF cell culture and treatments
Six culture conditions were applied on BALF cells
originating from both healthy and R.A.O.-affected
horses in remission:media alone, supplementationwith
LPS at 10 lg/mL, Aspergillus fumigatus at 80 cfu/mL
and hay dust suspensions at 1 lg/mL, 10 lg/mL and
100 lg/mL respectively. The cells were cultured in
RPMI 1640-L glutamine supplemented with 10%
heat-inactivated FCS and 1% penicillin-streptomycin
at 37 C and 5% CO2 for 6 and 24 h. Once the treat-
ment was completed, the supernatants of the culture
were collected from each well for measuring PTX3
protein. Cell pellets were immediately lyzed in SDS.
All collected samples were stored at 80 C in order
to perform Western blotting later.
2.6. Bronchial tissues from autopsy cases
Bronchial specimens were obtained within 2 h
after death from 2 horses affected by R.A.O., in
severe crisis and euthanized for ethical reasons, and
from 3 healthy horses from the slaughterhouse. The
specimens were directly mounted in Tissue-Tek
OCT compound and then snap-frozen and stored at
80 C. Cryostat tissue sections were performed
and used for immuno-histochemistry.
2.7. DNA isolation, PCR ampliﬁcation
Desoxyribo-nucleotide acid (DNA) was extracted
from peripheral blood nucleated cells originating
from humans and equines, using the QIAamp 96
DNA Blood Kit (Qiagen, Kjvebki, Belgium) and fol-
lowing the manufacturer’s instructions.
The PCR product was subjected to electrophore-
sis on agarose gel. It was then cloned into the cloning
vector pGEMT (Promega, Leiden, Netherlands).
Positive clones were identiﬁed by the restriction
enzyme FastDigest MluI (Fermentas, St. Leon-Rot,
Germany) and by analyzing the results on agarose
gel. The clones were submitted to sequencing.
2.8. RNA isolation, reverse transcription
and PCR ampliﬁcation
Equine blood was collected using Paxgene col-
lection tubes (Sanbion, Uden, Netherlands) and the
ribonucleotide acid (RNA) was extracted following
the manufacturer’s instructions. RNA concentration
and purity were measured with spectrophotometer
(Nanodrop, ThermoScientiﬁc, Wilmington, DE,
USA). The cDNA was synthesized and ampliﬁed
using the First Strand cDNA Synthesis kit for reverse
transcription-polymerase chain reaction (RT-PCR)
(Roche, Vilvoorde, Belgium) following the manufac-
turer’s instructions. The product was then submitted
to sequencing.
2.9. RT-qPCR
RT-qPCR was performed as previously described
[18]. In brief, RNAwas extracted from BALF macro-
phages using the RNeasy mini kit (Qiagen) and
RT-qPCR reactions were performed with IQ Sybr
Green Supermix (Bio-Rad, Nazareth, Belgium)
Table I. Primers.
Primers sequence 50 ! 30
PCR target/Genomic PTX3 exon2
Forward ACACACTGTTTTTCGGAGGTGTC
Reverse CGAGACATCCCAGAAGATAGCC
RT-PCR target/PTX3 cDNA
Forward GACAACGAAATAGACAATGGACTC
Reverse CTTTGTGCCATAGGAAAACAGGAT
Forward TCTGTGGCTTTGACCCAAATGC
Reverse GAAATAGACAATGGACTTCATCC
RT-qPCR target/PTX3
Forward TGGCCAAAACAAAAATAACCAG
Reverse GTGCTTTCAGATGAATGCTGT
RT-qPCR housekeeping gene/GAPDH
Forward CCTTCTCTTGCTGGGTGATTG
Reverse GACAATGAATTTGGCTACAGCA
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following the manufacturer’s instructions. The reac-
tion master mix was prepared as recommended by
the manufacturer in a ﬁnal volume of 20 lL. Samples
were normalized to equine GAPDH. The results were
analyzed with the ICycler software version 3.OA
(Bio-Rad) and a relative quantiﬁcation ofRNApresent
in the samples was performed using Pfafﬂ’smodel and
GAPDH gene expression as a reference [17].
2.10. Western blotting
Western blotting was performed as previously
described [2]. Brieﬂy, cultured BALF cell lysates
containing equal amounts of total protein and equal
amounts of culture supernatant were heated at
60 C with SDS 1% and bromophenol blue. They
were then subjected to SDS-PAGE. Proteins were
transferred onto a nitrocellulose membrane. The
membrane was blocked with 5% dry milk and probed
with the speciﬁc antibodies indicated. The rat IgG2b
isotype control and ﬁrst antibody omission were used
as negative controls. The blots were visualized with
an ECL detection kit.
2.11. Immuno-histochemistry
Cytospin preparations of fresh BALF cells
were performed. The cells were ﬁxed in periodate-
paraformaldehyde-lysine (PLP)-sucrose as previously
described [24]. Bronchial sections and cytospin
preparations were rehydrated in PBS for 5 min and
bronchial sections were treated with acetone for
10 min and methanol for 10 min. After blocking with
3% hydrogen peroxide for 20 min and 5% of albumin
from bovine serum for 30 min, the slides were
incubated for 90 min with either MNB1 monoclonal
antibody (1:50 dilution), a rat IgG2b isotype control
(1:50 dilution), or no Ab, followed by polyclonal
rabbit anti-rat immunoglobulins/HRP (1:100 dilution)
as secondary Ab. Detection was done by AEC sub-
strate chromogen. Slides were counterstained with
Mayer’s hematoxylin. For cytological evaluation,
cytospins were stained with May-Grumwald Giemsa.
2.12. Statistical analysis
Statistical analysis of the healthy and R.A.O.-
affected groups was performed by Anova using the
software Statview 4.01 (SAS Institute, Cary, NC,
USA). A p value of less than 0.05 was considered
signiﬁcant.
3. RESULTS
3.1. Characterization of equine PTX3
The blast identiﬁed three homology domains
between the human cDNA of PTX3 and the
equine genomic sequence of PTX3, localized
on horse chromosome 19. From UCSC, we
Figure 1. PTX3 speciﬁc antibody. (A) Using MNB1 human monoclonal primary antibody (which detects
the C-terminal extremity of the PTX3 protein in humans), Western blotting revealed distinct masses
for PTX3 protein corresponding to 32 and 42 kDa. (B) No band was detected using an IgG2b isotype
control. The Western blotting was obtained using BALF cell culture supernatant. The cells originated from
R.A.O.-affected horses in remission (named SN1 and SN2) and were challenged for 6 h with dust
suspension (10 lg/mL).
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identiﬁed a gap in the equine genomic sequence
corresponding to a part of the exon 2 of the
human PTX3.
Our DNA sequencing results conﬁrmed a
120 bp gap in the equine genomic region corre-
sponding to hPTX3 exon 2. The resulting pre-
dictive protein would thus be 340 aa long and
weigh 37.282 kDa. The cDNA nucleotide
sequence we obtained translated into a 235 aa
predictive protein weighing 27.153 kDa. The
Western blotting performed with BALF cell
culture medium revealed apparent molecular
masses of 32 and 42 kDa (Fig. 1).
Thus the equine PTX3 gene, located on
equine chromosome 19, seems to be organized
in three exons separated by two introns. Our
results also strongly suggest that an alternative
splicing occurs with deletion of the second exon
and results in the 32 kDa band on immunoblot.
The two predictive proteins maintain the
two cysteine residues and the canonical ‘‘pentr-
axin consensus signature’’ (HxCxS/TWxS).
The N-glycosylation Asparagine (Asn) site is
also conserved. Alignment analysis of hPTX3
and ePTX3, full length and spliced, aa
sequences (Clustal W., European Bioinformat-
ics Institute3) is shown in Figure 2.
A three-dimensional model for the pentraxin
domain in ePTX3 was generated from the high-
resolution crystal structure of human SAP using
Swiss Prot from Expasy.
3.2. Horse clinical status assessment
Clinical scores were signiﬁcantly different
between both groups (p < 0.05) after dust expo-
sure. The most sensitive value of impulse oscill-
ometry for R.A.O.-affected horse evaluation,
X5Hz [26] was signiﬁcantly different between
R.A.O.-affected horses (0.008 ± 0.004 kPa/
L/s) and controls (0.0104 ± 0.002 kPa/L/s).
The percentage of BALF neutrophils in
R.A.O.-affected horses (22.94 ± 3.4%) was sig-
niﬁcantly increased compared to controls
(12 ± 4.71%). The arterial blood oxygen partial
pressure was signiﬁcantly decreased in R.A.O.-
affected horses (86.4 ± 6.9 mmHg) when com-
pared to healthy horses (108.6 ± 5.9 mmHg).
3.3. Cells expressing PTX3 in airways
Cells able toproducePTX3 inhorses’ airways
were identiﬁed by immuno-histochemistry.
PTX3 was detected in BALF macrophages and
young neutrophils from both R.A.O.-affected
and healthy horses after dust exposure. The
signal appeared to be stronger in BALF cells
fromR.A.O.-affected horses. Itwas almost unde-
tectable in BALF cells from either healthy or
R.A.O.-affected horses at pasture (Fig. 3).
PTX3 was also detected in eosinophils from a
horse suffering from eosinophilia of unknown
origin. A strong positive reaction was observed
in foamy macrophages.
A positive immuno-histochemical reaction
(red) was seen in frozen sections of bronchi from
healthy and R.A.O.-affected horses, in bronchial
epithelial cells and in inﬁltrative inﬂammatory
cells (Fig. 4). In bronchial epithelial cells, it local-
ized at the apexof the cells just behind the ciliated
process. The staining seemed to be enhanced
in horses suffering from R.A.O. No staining
was found under negative control conditions.
3.4. Effect of dust on PTX3 expression
Following dust exposure, PTX3 was
increased in the supernatant originating from
horses suffering from R.A.O. (Fig. 5).
Since macrophages showed the strongest
positive reaction for anti-PTX3 antibody, we
investigated the effect of dust exposure on
PTX3 induction in this cell type further. PTX3
mRNA was over-expressed in BALF macro-
phages following dust exposure (Fig. 6). How-
ever, there was no signiﬁcant difference
between R.A.O.-affected horses and healthy
horses. Similarly, at the protein level, an
enhanced positive reaction for anti-PTX3 anti-
body was seen in macrophages following dust
exposure, in both healthyhorses and those suffer-
ing from R.A.O., though the reaction was stron-
ger in horses suffering from R.A.O. (Fig. 3).
A. fumigatus and LPS are both known to be
present in hay dust, a causative agent of R.A.O.,
and to induce PTX3 expression. Thus, we stud-
ied the involvement of each stimulus on BALF
cells ex vivo. The protein was detected in all
conditions, including in the control assay. There3 http://www.ebi.ac.uk/Tools/clustalw2/index.html.
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was no signiﬁcant variation between the differ-
ent conditions, neither in cell lysates nor in cul-
ture supernatant (results not shown).
4. DISCUSSION
The equine PTX3 gene, located on equine
chromosome 19 seems to be organized in three
exons separated by two introns. The two bands
detected by Western blot, at 32 and 42 kDa
strongly suggest an alternative splicing.
This result is supported by the fact that our
cDNA sequence obtained for PTX3 aligned
perfectly with Equus caballus cDNA clone
LeukoN4_5_F08_A026 50 (accession number:
CD464905). To the best of our knowledge, it
is the ﬁrst time PTX3 alternative splicing is
reported. Whether this event is due to the
120 bp deletion in the N-terminal domain,
and is thus speciﬁc to the horse, or occurs in
all species remains to be determined.
The C-terminal pentraxin-like domain of
equine PTX3 protein is well conserved. It
shares 94% of conserved aa and a similar pre-
dicted three-dimensional model with the human
protein [14]. This argues for a conserved func-
tion of this domain between species.
The C-terminal extremity is implicated in the
interaction with C1q and the subsequent activa-
tion of the complement [13]. The antiangio-
genic function of the protein is related to its
N-terminal extremity [3]. Moreover, binding
of PTX3 to Factor H depends on interactions
with both domains [4]. Thus, the alternative
forms of the protein observed in the horse
CLUSTAL 2.0.10 multiple sequence alignment 
E_PTX3_full      MHLPAILFCVLWSVVSAENSDDYELMYVNLDNEIDNGLHPTEDRTPCDCRREDSEWDKLF 60
E_PTX3_sp        MHLPAILFCVLWSVVSAENSDDYELMYVNLDNEIDNGLHPTEDR---------------- 44
H_PTX3           MHLLAILFCALWSAVLAENSDDYDLMYVNLDNEIDNGLHPTEDPTPCDCGQEHSEWDKLF 60
                 *** *****.***.* *******:*******************                  
E_PTX3_full      TMLENSQMREGMLLQATDDVLRGELQRLREELGRLAGRLAGPCAPAAPAEAGLARALAEL 120
E_PTX3_sp        ------------------------------------------------------------
H_PTX3           IMLENSQMRERMLLQATDDVLRGELQRLREELGRLAESLARPCAPGAPAEARLTSALDEL 120
E_PTX3_full      QQESRDAGRRLARLE-----------------------------------------GACE 139
E_PTX3_sp        ----------------------------------------------------------CE 46
H_PTX3           LQATRDAGRRLARMEGAEAQRPEEAGRALAAVLEELRQTRADLHAVQGWAARSWLPAGCE 180
                                                                           ** 
E_PTX3_full      TAVLFPMRSKKIFGSVHPARPLRLESFSACIWVKATDVLNKTILFSYGTKRNPYEIQLYL 199
E_PTX3_sp        TAVLFPMRSKKIFGSVHPARPLRLESFSACIWVKATDVLNKTILFSYGTKRNPYEIQLYL 106
H_PTX3           TAILFPMRSKKIFGSVHPVRPMRLESFSACIWVKATDVLNKTILFSYGTKRNPYEIQLYL 240
                 **:***************.**:************************************** 
E_PTX3_full      SSQSIVFVVGGEESKLVADTVVSLGRWTHLCSTWNSEKGRTSLWVDGELVASTVEMATGH 259
E_PTX3_sp        SSQSIVFVVGGEESKLVADTVVSLGRWTHLCSTWNSEKGRTSLWVDGELVASTVEMATGH 166
H_PTX3           SYQSIVFVVGGEENKLVAEAMVSLGRWTHLCGTWNSEEGLTSLWVNGELAATTVEMATGH 300
                 * ***********.****:::**********.*****:* *****:***.*:******** 
E_PTX3_full      VVPEGGILQIGQEKNGCCVGGGFDETLAFSGRLTGFNIWDHVLSNEEIRETGGAESCHIR 319
E_PTX3_sp        VVPEGGILQIGQEKNGCCVGGGFDETLAFSGRLTGFNIWDHVLSNEEIRETGGAESCHIR 226
H_PTX3           IVPEGGILQIGQEKNGCCVGGGFDETLAFSGRLTGFNIWDSVLSNEEIRETGGAESCHIR 360
                 :*************************************** *******************
E_PTX3_full      GNVVGWGVTEIQPHGGAQYVS- 340
E_PTX3_sp        GNVVGWGVTEIQPHGGAQYVS- 247
H_PTX3           GNIVGWGVTEIQPHGGAQYVS- 381
                 **:******************
Figure 2. Alignment analysis of amino acid (aa) residues for equine PTX3 full length (E_PTX3_full),
spliced (E_PTX3_sp) and human PTX3 (ptx3_H). *Residues in that column are identical in all sequences in
the alignment. (:) Conserved substitutions are observed. (.) Semi-conserved substitutions are observed. The
pentraxin canonical signature (H·C·S/TW·S/T) is underlined and the two cysteines conserved in all the
members of the pentraxin family are in bold. The N-glycosylation Asn site is in bold italics.
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provide an opportunity to gain better knowl-
edge of the implication of each domain in vivo.
The N-linked glycosylation site on the
C-terminal pentraxin-like domain of PTX3 is
conserved in the horse. It is probably responsi-
ble for the 5 kDa higher molecular weight
(32 and 42 kDa instead of 27 and 37 kDa
respectively) observed on Western blot under
reducing conditions when compared to the pre-
dicted molecular weight of the protein [1].
Using immuno-histochemistry, we deter-
mined that PTX3 protein is expressed in BALF
macrophages, young neutrophils and bronchial
epithelial cells in equines.
PTX3 over-expression observed in the
BALF supernatant from R.A.O.-affected horses
in crisis conﬁrmed previous results obtained in
BALF cells [18]. In BALF cells, macrophages
showed the strongest expression of PTX3. In
particular, there was a strong expression of
PTX3 by dust-activated foamy macrophages.
These ﬁndings corroborate previous results
[21], suggesting that the production of PTX3
is induced when macrophages differentiate into
foam cells. Both R.A.O.-affected and healthy
horses presented an exacerbation of PTX3
expression in their macrophages following dust
exposure. This suggests that a certain degree of
inﬂammation also occurs in healthy horses fol-
lowing dust exposure and that another cell type
than macrophages is implicated in the differ-
ence in airway PTX3 expression between
R.A.O.-affected horses and healthy horses upon
dust challenge.
Figure 3. PTX3 expression in BALF cells. Large straight black arrows indicate young neutrophiles, empty
arrows indicate macrophages, straight ﬁne black arrows indicate lymphocytes and angled black arrows
indicate mature neutrophiles. PTX3 immuno-staining appears in red. (A) BALF cells from a healthy horse at
pasture. (B) BALF cells from a healthy horse after two weeks of dust exposure. (C) BALF cells from an
R.A.O.-affected horse at pasture. (D) BALF cells from an R.A.O.-affected horse after two weeks of dust
exposure. (E) BALF cells from the same horse (R.A.O.-affected horse after two weeks of dust exposure) as in
(D) butusing an IgG2B isotype control (control experiment; similar results were obtained by omitting the
primary antibody). Magniﬁcation ·200. (A color version of this ﬁgure is available online at www.vetres.org.)
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More horses should be investigated to deﬁni-
tively conﬁrm these results but a stronger PTX3
immunohistologic signal was noticed in the
bronchial epithelial cells of horses suffering from
R.A.O. in crisis, in comparison with controls.
Considering epithelial cells as one of the major
cell types in the airways, PTX3 produced at this
level could play an important role in the inﬂam-
matory process. In lung epithelial cells, PTX3
expression is regulated by a JNK-dependant,
NFjB-independent pathway [10]. A comparable
mechanism could be involved in bronchial
epithelial cells. Such a differential regulatory
mechanism between hematopoietic and non-
hematopoietic cells is supported by the com-
pletely different responses of these two different
cell populations to glucocorticoid treatment [6].
This would be of particular interest because
PTX3 expression in respiratory epithelial cells
could thus be therapeutically targeted.
The fact that LPS, conidia and dust suspen-
sion challenges failed to induce PTX3 protein
production in BALF cells ex vivo suggests that
dust is not a direct inducer of PTX3. To support
this ﬁnding, PTX3 expression was observed in
rat lungs after LPS, hemorrhagic shock/resusci-
tation and mechanical ventilation but, in vitro,
lung epithelial cells did not respond either to
LPS or to mechanical stretch stimulation [16].
In addition, silica was shown to induce PTX3
release from monocytes + pneumocytes co-cul-
tures but neither in pneumocytes nor in mono-
cytes alone. Moreover, both silica and IL-1b
induced PTX3 expression in co-cultures but
Figure 4. PTX3 expression in tissue samples. PTX3 was constitutively expressed in bronchial epithelial
cells (straight arrows) and was localized at the apex just behind ciliated processes. It was also detected in
inﬁltrative inﬂammatory cells (angled arrows). (A) Bronchial section from a healthy horse. (B) Bronchial
section from a horse suffering from R.A.O. with over-expression of PTX3 in bronchial epithelial cells and an
increase of the number of inﬁltrative inﬂammatory cells expressing PTX3. (C) Control experiment carried out
using an IgG2b isotype showed no staining of PTX3 (the same results were obtained by omitting the primary
antibody). Magniﬁcation ·200. (A color version of this ﬁgure is available online at www.vetres.org.)
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no difference in PTX3 levels was detected upon
combined silica and IL-1b treatment compared
to IL-1b [12]. In another study, TNF-a but nei-
ther LPS nor mechanical stretch induced PTX3
in A549 lung epithelial cells [7]. A similar
effect of TNFa was also shown in BEAS-2B
bronchial epithelial cells [10]. TNF-a and IL-
1b are over-expressed in R.A.O.-affected
horses’ airways [9]. These cytokines could thus
be intermediate mediators for dust-induced
PTX3 expression in BALF cells.
We demonstrate that alternative splicing
occurs in PTX3 in horses. We also provide fur-
ther evidence that PTX3 is not directly induced
by dust exposure but rather by enhancers of
inﬂammatory mediators such as LPS, TNF-a
and IL-1b. Finally, the regulatory pathway
responsible for the induction of PTX3 in bron-
chial epithelial cells could be of interest because
it could provide a respiratory-speciﬁc target for
future treatments.
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Figure 5. PTX3 in BALF supernatant (10· concentrated) from healthy horses (SH1, SH2, SH3)
and R.A.O.-affected horses (SA1, SA2, SA3) after 2 weeks of dust exposure.
Figure 6. Relative gene expression of PTX3 normalized to GAPDH in BALF macrophages. The results
are given in % of the maximal value.
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